Close
x
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX Nov 30 2021 12:00
    57,064.87 -195.71 (-0.34%)
  • NIFTY Nov 30 2021 12:00
    16,983.20 -70.75 (-0.41%)
  • SENSEX Nov 30 2021 12:00
    57,064.87 -195.71 (-0.34%)
  • NIFTY Nov 30 2021 12:00
    16,983.20 -70.75 (-0.41%)
  • Nasdaq Nov 30 2021 04:30
    15,782.83 +291.17 ( +1.88%)
  • DJIA Nov 30 2021 04:30
    35,135.94 +236.60 ( +0.68%)
  • S&P 500 Nov 30 2021 04:30
    4,655.27 +60.65 ( +1.32%)
  • Hang Seng Nov 30 2021 02:10
    23,475.26 -376.98 (-1.58%)
  • Crude Oil Nov 30 2021 08:27
    5,088.00 -255.00 (-4.77%)
  • Gold Nov 30 2021 08:26
    48,070.00 +483.00 ( +1.01%)
  • Silver Nov 30 2021 08:26
    62,423.00 +783.00 ( +1.27%)
  • Copper Nov 30 2021 04:09
    729.90 -5.35 (-0.73%)
  • Pound / Rupee Dec 23 2016 22:30
    99.73 +0.54 ( +0.54%)
  • Dollar / Rupee Dec 23 2016 22:30
    74.83 +0.41 ( +0.55%)
  • Euro / Rupee Dec 23 2016 22:30
    84.59 +1.15 ( +1.37%)
  • Yen / Rupee Dec 23 2016 22:30
    0.66 +0.01 ( +2.25%)

J B Chemicals & Pharmaceuticals Ltd

BSE Code : 506943 | NSE Symbol : JBCHEPHARM | ISIN:INE572A01028| SECTOR : Pharmaceuticals |

NSE BSE
 
SMC up arrow

1,638.70

1.65 (0.10%) Volume 280564

30-Nov-2021 EOD

Prev. Close

1,637.05

Open Price

1,653.40

Bid Price (QTY)

0.00(0)

Offer Price (QTY)

1,638.70(31)

 

Today’s High/Low 1,670.00 - 1,612.40

52 wk High/Low 1,985.00 - 956.05

Key Stats

MARKET CAP (RS CR) 12661.13
P/E 27.65
BOOK VALUE (RS) 254.1357437
DIV (%) 825
MARKET LOT 1
EPS (TTM) 59.25
PRICE/BOOK 6.44655480629268
DIV YIELD.(%) 1.01
FACE VALUE (RS) 2
DELIVERABLES (%) 26.18
4

News & Announcements

17-Nov-2021

J B Chemicals & Pharmaceuticals Ltd - JB Chemicals & Pharmaceuticals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

13-Nov-2021

J B Chemicals & Pharmaceuticals consolidated net profit rises 32.42% in the September 2021 quarter

12-Nov-2021

J.B. Chem Q2 PAT up 32% YoY to Rs 98 crore

12-Nov-2021

J B Chemicals & Pharmaceuticals standalone net profit rises 24.54% in the September 2021 quarter

02-Nov-2021

J B Chemicals & Pharmaceuticals announces board meeting date

01-Oct-2021

J B Chemicals & Pharmaceuticals appoints CFO

31-Aug-2021

J B Chemicals & Pharmaceuticals CFO resigns

05-Aug-2021

J B Chemicals & Pharmaceuticals schedules board meeting

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Alembic Ltd 506235 ALEMBICLTD
Alembic Pharmaceuticals Ltd 533573 APLLTD
Alkem Laboratories Ltd 539523 ALKEM
ANG Lifesciences India Ltd 540694
Anglo-French Drugs & Industries Ltd 40169
Anupam Rasayan India Ltd 543275 ANURAS
Astron Drugs & Industries Ltd 524206
Aurobindo Pharma Ltd 524804 AUROPHARMA
Bajaj Healthcare Ltd 539872 BAJAJHCARE
Bal Pharma Ltd 524824 BALPHARMA
Biocon Ltd 532523 BIOCON
Bombay Drugs & Pharma Ltd (Merged) 524512
Brooks Laboratories Ltd 533543 BROOKS
Cadila Healthcare Ltd 532321 CADILAHC
Cebon India Ltd 524272
Celestial Biolabs Ltd 532871 CELESTIAL
Cepham Organics Ltd 507756
Cian Healthcare Ltd 542678
Cipla Ltd 500087 CIPLA
Claris Lifesciences Ltd 533288
Concord Drugs Ltd 538965
Dee-Pharma Ltd 507722 DEEPHARMA
Dishman Carbogen Amcis Ltd 540701 DCAL
Dr Reddys Laboratories Ltd 500124 DRREDDY
Dr Sabharwals Manufacturing Labs Ltd 507743
Dr.Datsons Labs Ltd 533412 DRDATSONS
Druid Pharma Ltd 40430
Earum Pharmaceuticals Ltd 542724
Eupharma Laboratories Ltd 530409 EUPHARMLAB
FDC Ltd 531599 FDC
Glenmark Life Sciences Ltd 543322 GLS
Glenmark Pharmaceuticals Ltd 532296 GLENMARK
Gufic BioSciences Ltd 509079 GUFICBIO
Hindustan Bio Sciences Ltd 532041
Hindustan Biotech Ltd 40162
Indoco Remedies Ltd 532612 INDOCO
Ind-Swift Laboratories Ltd 532305 INDSWFTLAB
IOL Chemicals & Pharmaceuticals Ltd 524164 IOLCP
Ipca Laboratories Ltd 524494 IPCALAB
Jagsonpal Pharmaceuticals Ltd 507789 JAGSNPHARM
Jayant Vitamins Ltd 506518
Jupiter Bioscience Ltd 524826 JUPITER
KDL Biotech Ltd 532291 KOPDRUGS
Kopran Ltd 524280 KOPRAN
Kothari Phytochemicals & Industries Ltd 40136
Lasa Supergenerics Ltd 540702 LASA
Lupin Laboratories Ltd (Merged) 500258 LUPINLAB
Lyka Labs Ltd 500259 LYKALABS
Mangalam Drugs and Organics Ltd 532637 MANGALAM
Medico Remedies Ltd 540937
Mercury Phytochem Ltd 524498
Merind Ltd 506895 MARIND
Mesco Pharmaceuticals Ltd 500274 MESCOPHARM
Morepen Laboratories Ltd 500288 MOREPENLAB
Mylan Laboratories Ltd 524794 MATRIXLABS
Natco Pharma Ltd 524816 NATCOPHARM
Oriental Remedies & Herbals Ltd 526989
Ortin Laboratories Ltd 539287 ORTINLAB
P C I Chemicals & Pharmaceuticals Ltd 524792
Pan Drugs Ltd 531440
Panacea Biotec Ltd 531349 PANACEABIO
Parnax Lab Ltd 506128
Phaarmasia Ltd 523620
Pharmaceutical Products of India Ltd 524113 PPIL
Piramal Enterprises Ltd 500302 PEL
Ranbaxy Laboratories Ltd (Merged) 500359 RANBAXY
RPG Life Sciences Ltd 532983 RPGLIFE
Saamya Biotech (India) Ltd 532905
Sakar Healthcare Ltd 538377 SAKAR
Sandoz (India) Ltd (Merged) 531990
Sharda Drugs & Industries Ltd 24206
Shree Ganesh Biotech India Ltd 539470
Shree Ganesh Remedies Ltd 540737
Siddhartha Pharmachem Ltd 532122
SMS Lifesciences India Ltd 540679 SMSLIFE
Socrus Bio Sciences Ltd 524719
SOL Pharmaceuticals Ltd 500393 SOLPHARMA
Solara Active Pharma Sciences Ltd 541540 SOLARA
Source Natural Foods & Herbal Supplements Ltd 531398
Strides Pharma Science Ltd 532531 STAR
Sumitra Pharmaceutical & Chemicals Ltd (Merged) 524133 SUMITRAPHA
Sun Pharmaceuticals Industries Ltd 524715 SUNPHARMA
Supriya Pharmaceuticals Ltd 524784
Surya Pharmaceutical Ltd 532516 SURYAPHARM
Suven Pharmaceuticals Ltd 543064 SUVENPHAR
Syngene International Ltd 539268 SYNGENE
Syschem (India) Ltd 531173
Themis Medicare Ltd 530199 THEMISMED
Titan Biotech Ltd 524717
Tonira Pharma Ltd(merged) 530155
Torrent Pharmaceuticals Ltd 500420 TORNTPHARM
Triochem Products Ltd 512101
TTK Healthcare Ltd 507747 TTKHLTCARE
Unichem Laboratories Ltd 506690 UNICHEMLAB
Unicorn Pharmaceuticals (India) Ltd 524334
Valencia Nutrition Ltd 542910
Vardhaman Laboratories Ltd 524796
Vikram Thermo (India) Ltd 530477
Vineet Laboratories Ltd 543298 VINEETLAB
Vivimed Labs Ltd 532660 VIVIMEDLAB
Welcure Drugs & Pharmaceuticals Ltd 524661
Wintac Ltd 524758
Wockhardt Ltd 532300 WOCKPHARMA
Zillion Pharmachem Ltd 524476 ZILONPHARM
Zota Health Care Ltd 538426 ZOTA

Share Holding

Category No. of shares Percentage
Total Foreign 7670744 9.93
Total Institutions 11775441 15.24
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 678010 0.88
Total Promoters 43205625 55.91
Total Public & others 13953088 18.06
Total 77282097 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About J B Chemicals & Pharmaceuticals Ltd

J B Chemicals & Pharmaceuticals (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals in December 18th, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and APIs. The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000. Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines. In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment i.e., Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new products Cephalosporins, Moviz and its expansion Movi 3D and a nueropsychiatry product through Zephyr for the first time. A 100% EOU manufacturing facility at Panoli for production of Gel, Ointment was commissioned during 2001-02 at a cost of Rs.21 crores and the same was financed through internal accruals. To manufacture 'DOKTOR MOM' lozenges the company is setting up two manufacturing units at Daman at a capital outlay of Rs.28 crores, which is to be financed through internal accruals. The commercial production of the Doktor Mom lozenges at its 100% Export Oriented Unit, started from 1 Sep. 2003 and tablets from 1, Jan. 2004 in Daman.Doktor Mom', the company's brand,was adjudged the Most Trusted European Brand by Reader's Digest in the cold and cough segment for the fourth consecutive year in 2003-04. During 2004-05, the company received approval for its pharmaceutical manufacturing unit from TGA (Australia). During 2004-05, the company plants were approved by US-FDA, TGA-Australia, EDQM, MCC-South Africa, INVIMA (Colombia) and MHRA (UK). During 2004-05, the company is setting up a new facility conforming to international standards in Panoli (Gujarat) to manufacture contrast media products by June 2006. During 2004-05, the company has planned to set up a wholly owned subsidiary in Moscow, Russia, called 'Unique Pharmaceuticals Laboratories' with the initial investment of $ 3 million. During 2005, the company entered into two agreements, one with Pharma-a-Care Pharmaceuticals Pte. Ltd., in Australia to develop its niche products in Australian market and another with Ranbaxy Laboratories to enter in the Romanian market. The company has subdivided the value of the share from Rs.10/- per share to Rs.2/- per share with effective from 05, April 2005. During 2005-2006, the company has proposed to amalgamate its wholly owned subsidiary viz. lekar healthcare ltd with itself. The company has fixed April 1, 2006 as the appointed date. During the year 2015, J.B. Chemicals & Pharmaceuticals Private Limited, Singapore, ceased to be the company's subsidiary consequent to its dissolution. The Scheme of Amalgamation and Arrangement between Jyotindra Mody Holdings Private Limited and Ansuya Mody Securities Private Limited and Dinesh Mody Securities Private Limited and Kumud Mody Securities Private Limited and Shirish B. Mody Investments Private Limited and Bharati S. Mody Investments Private Limited (Transferor Companies) and J. B. Chemicals & Pharmaceuticals Limited (Transferee Company) and their respective shareholders under Sections 391 to 394 read with Sections 100 to 103 of the Companies Act, 1956 and Section 55 of the Companies Act, 2013 and any other applicable provisions of the Companies Act, 1956 and the Companies Act, 2013, which was approved by the Board on 15 April 2014 and members of the company at Court Convened Meeting held on 14 October 2014 and public shareholders through postal ballot and e-voting on 16 October 2014, was sanctioned by the Hon'ble Bombay High Court on 27 February 2015. The Scheme has become effective on 13 April 2015 with appointed date of 1 April 2014. Accordingly, the Transferor Companies stand merged with the company and the merger has been given effect to in the financial statements of the company for the year ended on March 31, 2015. Consequently, 4,33,42,270 equity shares of FY Rs. 2 held by the Transferor Companies in the company have been cancelled and the company has allotted 4,33,42,270 equity shares of Rs. 2 each credited as fully paid up to the shareholders of the Transferor Companies in accordance with the fair share entitlement ratio specified in the Scheme. During the year 2016, the Company's subsidiary Unique Pharmaceutical Laboratories FZE (UPL FZE) acquired 2, 194,030 Ordinary Shares in Biotech Laboratories (Pty.) Ltd. from Afrika Biopharma Investments (Pty). Ltd. Consequent to restructuring of existing 49% shareholding in Biotech and issue of certain shares by Biotech after the aforesaid acquisition, UPL FZE now holds 95.24% voting capital of Biotech. Accordingly, Biotech has become subsidiary of the Company. Subsequently, the Company's subsidiary J.B. Healthcare Pvt. Ltd., Jersey, has been dissolved. With a view to return surplus cash and pursuant to authority conferred under the Articles of Association of the Company, the Board approved buy-back of fully paid up equity shares of face value of Rs 2 by the Company up to 12,50,000 equity shares at a price of Rs 400 per equity share for a total consideration not exceeding Rs 5,000 lakhs (buy-back amount) excluding transaction costs, on proportionate basis through tender offer. The number of equity shares authorized for buy-back represents 1.47% of the total outstanding equity shares, while the buy-back amount represents 3.85% of the equity share capital and free reserves as at March 31, 2017. This buy-back will be implemented in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. The Company completed on 25 July 2017 buy-back of 1,250,000 equity shares of face of Rs. 2 at price of Rs. 400 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 83,569,975 equity shares of Rs. 2. The Company has transferred the sum of Rs. 25 lakhs from general reserves to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013. The Company launched four new products in dermatology, amoebicide and probiotic segments during the year 2018. The Company completed on 1st November 2018 buy-back of 3,333,333 equity shares of face value of Rs 2 at price of Rs 390 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 80,236,642 equity shares of Rs 2. The Company has transferred the sum of Rs 66.67 lakhs from general reserve to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013.

J B Chemicals & Pharmaceuticals Ltd Chairman Speech

Dear Shareholders,

Our ‘One JBCPL’ family has completed its 44th year. Being one of the fastest-growing pharmaceutical companies in India, we have good reason to be pleased. Even so, we are not content. We are already looking ahead and accelerating towards our 50th year in 2025. In this journey, we will focus on strengthening our core capabilities and also build an organisation that is agile and resilient to uncertain times.

Before discussing the future, I would like to express my heartfelt thanks to all those who have been battling Covid-19 for over a year by working tirelessly and selflessly to mitigate the impact of this pandemic. Covid-19 has shifted the method and pace of healthcare delivery. It has sensitised us to the need for greater speed, integration and quality of response across manufacturing, supply chain, sales, marketing, quality control and assurance (QA-QC), and R&D.

At JBCPL, we are applying our learnings to establish plans for the future.

Business transformation initiatives:

Our major focus is to strengthen our core therapy segments i.e. hypertension, gastroenterology, nephrology, cardiology, dentistry, and paediatrics. In FY 21 we realigned our structure and portfolio to ensure sustainable growth and put a strong focus on the lifecycle management of our flagship brands.

The next priority is to scale up R&D and business development initiatives towards building a progressive portfolio for our US, ROW, Russia, SA, API, and CMO businesses.

We will focus on consolidating our business areas through a deeper presence in existing geographies, this will be aided by new launches over the next 2-3 years.

We are investing in ‘beyond the pill’ initiatives, tech-enabled solutions, and a ‘phygital’ approach to innovatively meet the diverse needs of internal stakeholders, employees, associates, and HCPs (Healthcare Professionals).

Moving into newer therapeutic categories:

In the past few months, we have ventured deeper into therapeutic segments where we already have equity, as well as expanded into adjacent therapies where we believe we can enhance the quality of care for patients.

Nephrology - We have introduced a range of products to support the treatment of kidney disease. These will leverage our formidable equity with nephrologists and further expand our market share in this category.

Respiratory - Respiratory diseases are the most common disease conditions which impact every socio-economic and age group in society. We have introduced a comprehensive portfolio for treating respiratory allergy, virology and ILD.

Diabetes - We entered the fastest-growing category of the Indian pharmaceuticals market with the launch of DPPIV and SGLT2 inhibitor molecules. These leverage our strength in the cardio-metabolic segment.

Nicotine Replacement Therapy (NRT) - We extended our lozenges expertise to Nicotine Replacement Therapy in India with introduction of our NOSMOK lozenges.

Adding and upgrading resources & processes:

We have hired leaders for key positions in the domains of R&D, QA-QC, IR, Legal, Company Secretary, and Finance to strengthen our expertise and operate with the highest standards of governance and control. We now have a good mix of talent and able leadership in place to meet our aspirations for 2025.

We are exploring possible M&A opportunities which can complement our strengths and accelerate our performance in key segments.

Structured programs in the organisation aimed at improving our supply, service, and cost-efficiency. This will enhance our profitability and business growth.

All these initiatives are being carried out with full commitment and passion towards one singular purpose, which is to do more good for more people. However large and successful our business becomes, we will always retain the spirit of JBCPL.

We believe that we are big enough to create a positive impact for patients and healthcare providers, yet small enough to still care.

   

J B Chemicals & Pharmaceuticals Ltd Company History

J B Chemicals & Pharmaceuticals (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals in December 18th, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and APIs. The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000. Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines. In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment i.e., Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new products Cephalosporins, Moviz and its expansion Movi 3D and a nueropsychiatry product through Zephyr for the first time. A 100% EOU manufacturing facility at Panoli for production of Gel, Ointment was commissioned during 2001-02 at a cost of Rs.21 crores and the same was financed through internal accruals. To manufacture 'DOKTOR MOM' lozenges the company is setting up two manufacturing units at Daman at a capital outlay of Rs.28 crores, which is to be financed through internal accruals. The commercial production of the Doktor Mom lozenges at its 100% Export Oriented Unit, started from 1 Sep. 2003 and tablets from 1, Jan. 2004 in Daman.Doktor Mom', the company's brand,was adjudged the Most Trusted European Brand by Reader's Digest in the cold and cough segment for the fourth consecutive year in 2003-04. During 2004-05, the company received approval for its pharmaceutical manufacturing unit from TGA (Australia). During 2004-05, the company plants were approved by US-FDA, TGA-Australia, EDQM, MCC-South Africa, INVIMA (Colombia) and MHRA (UK). During 2004-05, the company is setting up a new facility conforming to international standards in Panoli (Gujarat) to manufacture contrast media products by June 2006. During 2004-05, the company has planned to set up a wholly owned subsidiary in Moscow, Russia, called 'Unique Pharmaceuticals Laboratories' with the initial investment of $ 3 million. During 2005, the company entered into two agreements, one with Pharma-a-Care Pharmaceuticals Pte. Ltd., in Australia to develop its niche products in Australian market and another with Ranbaxy Laboratories to enter in the Romanian market. The company has subdivided the value of the share from Rs.10/- per share to Rs.2/- per share with effective from 05, April 2005. During 2005-2006, the company has proposed to amalgamate its wholly owned subsidiary viz. lekar healthcare ltd with itself. The company has fixed April 1, 2006 as the appointed date. During the year 2015, J.B. Chemicals & Pharmaceuticals Private Limited, Singapore, ceased to be the company's subsidiary consequent to its dissolution. The Scheme of Amalgamation and Arrangement between Jyotindra Mody Holdings Private Limited and Ansuya Mody Securities Private Limited and Dinesh Mody Securities Private Limited and Kumud Mody Securities Private Limited and Shirish B. Mody Investments Private Limited and Bharati S. Mody Investments Private Limited (Transferor Companies) and J. B. Chemicals & Pharmaceuticals Limited (Transferee Company) and their respective shareholders under Sections 391 to 394 read with Sections 100 to 103 of the Companies Act, 1956 and Section 55 of the Companies Act, 2013 and any other applicable provisions of the Companies Act, 1956 and the Companies Act, 2013, which was approved by the Board on 15 April 2014 and members of the company at Court Convened Meeting held on 14 October 2014 and public shareholders through postal ballot and e-voting on 16 October 2014, was sanctioned by the Hon'ble Bombay High Court on 27 February 2015. The Scheme has become effective on 13 April 2015 with appointed date of 1 April 2014. Accordingly, the Transferor Companies stand merged with the company and the merger has been given effect to in the financial statements of the company for the year ended on March 31, 2015. Consequently, 4,33,42,270 equity shares of FY Rs. 2 held by the Transferor Companies in the company have been cancelled and the company has allotted 4,33,42,270 equity shares of Rs. 2 each credited as fully paid up to the shareholders of the Transferor Companies in accordance with the fair share entitlement ratio specified in the Scheme. During the year 2016, the Company's subsidiary Unique Pharmaceutical Laboratories FZE (UPL FZE) acquired 2, 194,030 Ordinary Shares in Biotech Laboratories (Pty.) Ltd. from Afrika Biopharma Investments (Pty). Ltd. Consequent to restructuring of existing 49% shareholding in Biotech and issue of certain shares by Biotech after the aforesaid acquisition, UPL FZE now holds 95.24% voting capital of Biotech. Accordingly, Biotech has become subsidiary of the Company. Subsequently, the Company's subsidiary J.B. Healthcare Pvt. Ltd., Jersey, has been dissolved. With a view to return surplus cash and pursuant to authority conferred under the Articles of Association of the Company, the Board approved buy-back of fully paid up equity shares of face value of Rs 2 by the Company up to 12,50,000 equity shares at a price of Rs 400 per equity share for a total consideration not exceeding Rs 5,000 lakhs (buy-back amount) excluding transaction costs, on proportionate basis through tender offer. The number of equity shares authorized for buy-back represents 1.47% of the total outstanding equity shares, while the buy-back amount represents 3.85% of the equity share capital and free reserves as at March 31, 2017. This buy-back will be implemented in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. The Company completed on 25 July 2017 buy-back of 1,250,000 equity shares of face of Rs. 2 at price of Rs. 400 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 83,569,975 equity shares of Rs. 2. The Company has transferred the sum of Rs. 25 lakhs from general reserves to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013. The Company launched four new products in dermatology, amoebicide and probiotic segments during the year 2018. The Company completed on 1st November 2018 buy-back of 3,333,333 equity shares of face value of Rs 2 at price of Rs 390 per share on proportionate basis through tender offer in accordance with provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Buy-back of Securities) Regulations, 1998. Consequently, the paid-up equity share capital stands reduced to 80,236,642 equity shares of Rs 2. The Company has transferred the sum of Rs 66.67 lakhs from general reserve to capital redemption reserve account pursuant to Section 69 of the Companies Act, 2013.

J B Chemicals & Pharmaceuticals Ltd Directors Reports

Your directors are pleased to present forty-fifth report and audited financial statement of the Company for the financial year ended on March 31, 2021.

1. FINANCIAL HIGHLIGHTS

The following are the highlights of financial performance of the Company during the year under review . (Rs. in lakhs)

2020-21 2019-20
Sales 184,907.75 160,619.62
Other Operating revenue 4,291.80 3,454.82
Other Income 11,188.94 4,934.27
Total Income 200,388.49 169,008.71
Profit before finance cost and depreciation 66,825.48 41,758.73
Less: Finance cost 719.18 293.51
Less: Depreciation & Amortisation expense 6,735.50 6,509.05
Profit before exceptional item and tax 59,370.80 34,956.17
Exceptional Item ? 1,000.00
Profit before tax 59,370.80 33,956.17
Tax Expense (Net) 14,662.32 7,141.77
Net Profit after tax 44,708.48 26,814.40
Other Comprehensive Income (1,249.67) (506.42)
Total Comprehensive Income after tax 43,458.81 26,307.98
Earnings per share of Rs.2 (in Rs.) (Basic & Diluted) 57.85 33.70

2. DIVIDEND

Your directors recommend a final dividend ofRs. 8 (400%) per equity share of face value of Rs. 2, payment whereof will be subject to deduction of tax at source. During the year, Board of directors declared interim dividend of Rs. 8.50 (425%) per equity share, which was paid on 5-3-2021. The final dividend, if declared, together with interim dividend already paid would result in total outgo of Rs. 127.52 crores. The Board has not proposed any transfer out of profit for the financial year to reserves in relation to these dividend payments. The Company paid interim dividend of Rs. 10 (500%) and final dividend of Rs. 1 (50%) per equity share in the previous year.

3. CHANGE IN CONTROL

Pursuant to Share Purchase Agreement dated 2-7-2020 entered into between founder Mody Family members and Tau Investment Holdings Pte. Ltd., Singapore, an affiliate of global private equity firm KKR, Tau Investment Holdings Pte. Ltd. acquired controlling stake of 41,731,363 (54%) equity shares of Rs. 2 each in the Company from Mody Family members. Consequently, Mody Family members having representation on the Board and occupying senior management positions resigned, following which other directors on the Board appointed prior to 2-7-2020 also resigned due to their personal reason. Hence, the Board of directors was re-constituted on 31-8-2020. The details of appointment and resignation of directors in the course of such re-constitution are set out in paragraph 10 below.

Following execution of the above referred Share Purchase Agreement to acquire shares in and control over the Company, Tau Investment Holdings Pte. Ltd. and persons acting in concert made an open offer for acquisition of 20,093,346 shares (26%) @ Rs. 745 per share from public shareholders of the Company as per provisions of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

4. OPERATIONS/STATE OF AFFAIRS

The financial year 2020-21 was eventful as the Company saw change of control and management on one hand and witnessed unprecedented business environment due to COVID-19 on the other. There was no major impact of COVID-19 on business of the Company. Company’s manufacturing facilities continued to operate but with some impact of restrictions on movement of people and materials due to COVID-19.

Total standalone sales during the year at Rs. 1,849.08 crores were 15.1% higher over the previous year, while EBITDA at Rs. 556.37 crores grew by 51.09% and was 29.4% of operating revenue.

Domestic formulations business at sales of Rs. 839.07 crores registered growth of 14.1% over the previous year against industry growth of 4% MAT March 2021). This robust performance was enabled ( by strong performance of Company’s key brands. In this business, the Company has implemented a new ‘go to market’ model with focus on productivity and driving progressive product portfolio, which should aid the performance in this business. Sales of contrast media products in the domestic market at Rs. 52.83 crores were 14% lower over the previous year due to COVID-19.

Overall formulations exports at Rs. 850.55 crores registered growth of 19.6% over the previous year. Exports to Rest of the World markets (other than Russia-CIS) with sales of Rs. 626.52 crores achieved good growth of 24.8%. The sales to US market and sales of branded generics products to other markets in this business achieved growth of 63% and 18% respectively. Sales to Russia-CIS market at Rs. 130.59 crores achieved growth of 4% as the demand in local markets was impacted by COVID-19 consequences. API sales at Rs. 81.79 crores achieved growth of 17.7% over the previous year.

Profitbefore tax at Rs. 593.71 crores registered growth of 74.85% mainly due to higher sales of chronic segment products, lower than normal operating cost during most part of the year due to COVID-19, favourable exchange rate during first half of the year and higher other income. Profit after tax atRs. 434.58 crores consequently grew by 65.19%.

5. RESPONSIBILITY STATEMENT

The directors confirm:

(i) that in the preparation of the annual accounts for the year under review, the applicable accounting standards have been followed;

(ii) that they have selected appropriate accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of financial year 2020-21 and of profit of the Company for that

(iii) that they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(iv) that they have prepared the annual accounts for the year ended on March 31, 2021 on a going concern basis;

(v) that they have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and that there was (vi) that they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

6. SUBSIDIARIES

The highlights of performance of subsidiary companies in Rupee terms for the year 2020-21 is presented in Schedule-A. After inter-company adjustments, subsidiary companies contributed Rs. 151.02 crores to consolidated income and Rs. 3.18 crores to consolidated profit before tax of the Company. Sales of Biotech Laboratories (Pty.) Ltd., South Africa, for the financial year 2020-21 were Rand 477.19 million, which represents growth of 35.51% over the previous year, while its operating profit and profit after tax at Rand 34.58 million and Rand 25.67 million were 90.08% and 71.52% higher over the previous year respectively. Sales of LLC Unique Pharmaceutical Laboratories, Russia, for the financialyear 2020-21, at Ruble 653.58 million were 9.1% lower over the previous year, while it incurred loss of Ruble 1.45 million against profit of Ruble 4.03 million in the previous year. Unique Pharmaceutical Laboratories FZE, Dubai is presently not engaged in any business activity. It earned net profitof AED 26,080 due to exchange gain.

7. CORPORATE GOVERNANCE AND COMPLIANCES

A certificate from practising company secretary on comliance with conditions of corporate governance is annexed to this Board’s report. Management Discussion and Analysis Report, Compliance report on Corporate Governance, Business Responsibility Report and Dividend Distribution Policy form part of this annual report.

8. PUBLIC DEPOSITS

The Company has not accepted any deposit covered under Chapter V of the Companies Act, 2013 during the year. All the public deposits accepted prior to the commencement of the said Act have been repaid in 2014-15.

9. TRIBUTE TO MR. JYOTINDRA B. MODY

Board has to inform the members with immense grief that Mr. J. B. Mody, founder Chairman and managing director of the Company since incorporation of the Company passed away on 21-07-2020. Mr. J. B. Mody built businesses, built brands and built organisation over the years through his vision, sheer entrepreneurship, deep focus and commitment. He played a vital role in growth of the Company and development of the businesses. Board has placed his valuable contributions on record with sense year; of gratitude.

10. DIRECTORS

Board appointed Mr. Ranjit Shahani, Mr. Sumit Bose and Ms. Padmini Khare Kaicker as additional directors (independent directors) and Mr. Sanjay Nayar, Mr. Prashant Kumar, Mr. Ajay Candade, Ms. Ananya Tripathi and Mr. Mayank Mishra as additional directors (non-executive) on 31-8-2020. Mr. Shirish B. Mody, Whole time director (Marketing), Mr. Bharat P. Mehta, Whole time director (Planning & Development), Mr. Kamlesh L. Udani, Executive director (Technical & Production), and Dr. Satyanarain Agarwala, Mr. Rajiv Mody, Ms. Krupa Gandhi, Mr. Devang Shah, Mr. Shaukat Merchant and Dr. Manoj Mashru, independent directors, resigned on 31-8-2020. These independent directors resigned because of their personal reason and they all confirmed no other material reason for their resignation. Mr. Pranabh Mody stepped down from his executive position of President and Whole time director (Operations) on 31-8-2020 and resigned as director on 9-11-2020.

The members of the Company at annual general meeting held on 30-9-2020 appointed Mr. Ranjit Shahani, Mr. Sumit Bose and Ms. Padmini Khare Kaicker as independent directors for a term of five years from 31-8-2020 and Mr. Sanjay Nayar, Mr. Prashant Kumar, Mr. Ajay Candade, Ms. Ananya Tripathi and Mr. Mayank Mishra as directors liable to retire by rotation. Subsequent to this, Mr. Ajay Candade resigned on 5-10-2020 and Mr. Mayank Mishra resigned on 10-2-2021.

Board appointed Mr. Nikhil Chopra as additional director on 5-10-2020 and also appointed him as Chief Executive Officer and Whole-time director of the Company on the even date. The members appointed Mr. Nikhil Chopra as director of the Company and also approved his appointment as Chief Executive Officer and Whole-time director and remuneration payable to him as such on 23-12-2020.

Board appointed Mr. Gaurav Trehan as additional director on 10-2-2021, who holds office up to the date of ensuing annual general meeting. The Company has received, a notice from a member proposing candidature of Mr. Gaurav Trehan to the office of director of the Company,pursuantto Section 160 of the Companies Act, 2013. It is proposed to appoint Mr. Gaurav Trehan as non-executive director of the Company. Mr. Gaurav Trehan is Partner and Head of the Private Equity business for KKR India and possesses expertise in the areas of business strategy, business management and corporate governance. His detailed profile is given in notice for the ensuing annual general meeting. This profile is deemed to form part of this report.

In accordance with provisions of the Companies Act, 2013, Ms. Ananya Tripathi would retire by rotation at the ensuing annual general meeting. Being eligible, she has offered herself for re-appointment.

In the opinion of the Board of directors, Mr. Ranjit Shahani, Mr. Sumit Bose and Ms. Padmini Khare Kaicker, independent directors, are persons of integrity and they all possess relevant expertise and experience necessary for effective functioning of the Company. These independent directors have given declarations to the Board that they meet the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 as well as in Regulation 16 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. They have also confirmed that they have registered with the Indian Institute of Corporate Affairs to include their names in the databank of independent directors. However, in terms of Companies (Appointment and Qualification of Directors) Rules, 2014 as amended, these independent directors are not required to test conducted by the passanonlineproficiency said Institute notified under sub-section (1) of Section 150 of the Companies Act, 2013.

Total eight (8) meetings of the Board of directors were held during the financial year 2020-21. They were held on June 25, 2020, July 14, 2020, August 25, 2020, August 31, 2020, September 14, 2020, October 5, 2020, November 10, 2020 and February 10, 2021.

11. POLICY ON DIRECTORS’ APPOINTMENT AND REMUNERATION POLICY

The Company’s policy on directors’ appointment is set out in Schedule-B. The salient features of the Company’s policy on remuneration for the directors, key managerial personnel and other employees is set out in Schedule-C. The said Policy including and criteria for determining independence of a director has been posted on the Company’s website www.jbcpl.com.

12. CONSERVATION OF ENERGY, TECHNOLOGY ABSORTION, FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars as required under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 are given in Schedule-D.

13. CORPORATE SOCIAL RESPONSIBILITY

Corporate Social Responsibility (CSR) Committee of the Board consists of Mr. Ranjit Shahani, Mr. Sumit Bose, Mr. Nikhil Chopra and Ms. Ananya Tripathi. The CSR Committee formulated and recommended revised CSR Policy to the Board, which the Board approved on 10-2-2021. The salient features of the revised CSR Policy of the Company and the annual report on CSR in the prescribed form are set out in Schedule-E. The CSR Policy and annual report on CSR are posted on the Company’s website www.jbcpl.com.

The Company spent Rs. 516.75 lakhs on prescribed CSR activities during financial year 2020-21 as against obligation ofRs. 509.35 lakhs being 2% of the average net profits of the Company made during three immediately preceding financial years.

14. AUDIT COMMITTEE AND VIGILANCE MECHANISM

The Board has constituted Audit Committee that consists of Ms. Padmini Khare Kaicker, Chairperson, Mr. Ranjit Shahani, Mr. Sumit Bose and Mr. Prashant Kumar. There has been no instance of non-acceptance of recommendation of Audit Committee by the Board.

The Board of directors has, on 10-11-2020, adopted revised vigil mechanism in the form of Whistle Blower Policy to enable directors, employees and other stakeholders to make Protected Disclosures (as defined in the Policy) in relation to Alleged Wrongful Conduct (as defined in the Policy) to the Redressal Committee for evaluation and investigation in consultation with the Audit Committee. The Policy empowers the Redressal Committee to initiate inquiry and investigation if the issue raised constitutes bona fide Protected Disclosure made in good faith. The Redressal Committee is required to complete the investigation in a time bound manner. Where it concludes that Unethical and/or Improper Activity (as defined in the Policy) has been committed, it shall recommend, after consultation with the Audit Committee, to the management of the Company to take such disciplinary or corrective action as it or the Audit Committee deems fit. The Policy provides for access of whistle blower to the Chairman of the Audit Committee in appropriate or exceptional circumstances. The Policy provides for adequate safeguards of whistle blowers against any kind of victimisation or unfair treatment but also provides for taking stern disciplinary action against who abuses the protection so granted. This functioning of vigil mechanism will be periodically reviewed by the Audit Committee. The Company has posted the Whistle Blower Policy and the associated Complaint Response Plan Policy on its website www.jbcpl.com.

15. ANNUAL PERFORMACE EVALUATION

The Board of Directors carried out formal annual evaluation of performance of the Board, its Committees and individual directors during 2020-21 in accordance with the manner specified by the Nomination and Remuneration Committee (NRC) and using evaluation criteria recommended by the NRC and approved by the Board. The performance evaluation was carried out in the following manner, being manner recommended by the NRC.

Evaluation of performance of the Board: Each member of the Board evaluated the Board on the given criteria on scale of 1 to 4 (4 being highest). The aggregate of simple average of rating assigned by each Board member was further averaged to ascertain Board’s performance.

Evaluation of performance of the Board Committees: Each member of the concerned committee evaluated performance of the committee on the given criteria on scale of 1 to 4. Aggregate of simple average of rating assigned by each such member was further averaged to ascertain performance of the concerned committee.

Evaluation of performance of Individual Director: Each Board member (excluding director being evaluated) evaluated performance of all other Board members on the given criteria on scale of 1 to 4. Aggregate of simple average of rating assigned to each Board member was further averaged to ascertain performance of such director.

16. CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

Form AOC-2 prescribed under Section 134(3)(h) read with Rule 8(2) of the Companies (Accounts) Rules, 2014 provides for disclosure of (a) details of contracts or arrangements or transactions not at arm’s length basis, and (b) details of material contracts or arrangement or transactions at arm’s length basis.

All the transactions entered into by the Company with the related parties during the year were pursuant to the contract or arrangement approved by the Audit Committee and the Board of Directors. The transactions so entered into were in the ordinary course of business of the Company and on arm’s length basis. The contract or arrangement or transactions were neither material in terms of the Policy on materiality of related party transactions adopted by the Company nor it exceeded the threshold limit prescribed pursuant to first proviso to Section 188(1) of the Companies Act, 2013. However, without going by the materiality as aforesaid, the details of material/major related party contracts/arrangement/ transactions at arm’s length basis and entered into in the ordinary course of business of the Company are given in Form No. AOC-2 given under Schedule-F1.

Every related party contract or arrangement entered into with approval of the Board under Section 188(1) of the Companies Act, 2013 is referred to in Schedule-F2 pursuant to Section 188(2) of the Companies Act, 2013. These contracts or arrangements are in the ordinary course of business and terms thereof are on arm’s length basis, and have been approved by the Audit Committee and the Board of Directors.

17. PARTICULARS OF EMPLOYEES AND OTHER REMUNERATION RELATED DISCLOSURES

The remuneration related and other disclosure required in terms of Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended, are given in Schedule-G.

A statement showing name and other particulars of the employees in terms of Section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended, is given in Schedule-H.

18. EMPLOYEE STOCK OPTION SCHEME

Board, on 28-4-2021 read with modifications/additions approved on 14-6-2021, basis of recommendation of the Compensation Committee, has approved a new employee stock option scheme termed as "JBCPL Employee Stock Option Scheme 2021" ("Scheme") for eligible employees and directors of the Company with a view to make the Company one of the attractive companies in the pharmaceutical industry with long term wealth creation opportunity for its employees linked to the Company’s long term growth. The Scheme is in terms of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014, and is subject to approval by members of the Company. 3,091,284 equity shares of Rs. 2 each, being 4% of the paid-up equity share capital of the Company as on March 31, 2021, have been reserved under the Scheme. The Company proposes to issue time-based options and performance-based options under the Scheme on such terms and conditions as determined by the Board/Compensations Committee from time to time.

The disclosure of details in respect of employee stock option scheme set-up with approval of the members of the Company granted at extra ordinary general meeting held on 18-3-2004 (‘the said old scheme"), as required under the Companies (Share Capital and Debentures) Rules, 2014, is set out in Schedule-I to this report. There was no grant, vest, exercise or lapse of options during the year under the said old scheme. There was no change in the said old scheme during the year and it is in compliance with SEBI (Share Based Employee Benefits) Regulations, 2014. Disclosure in respect of the said old scheme required in terms of SEBI Circular CIR/CFD/POLICY CELL/2/2015 dated June 16, 2015 are posted on the Company’s website www.jbcpl.com and web link thereto is https://www.jbcpl.com/investors/pdf/2021Rs.2022ESOPd31032021. pdf. As the said old scheme is not operational for long time and the Company does not plan to use the same and further that all options granted under the said old scheme are either exercised or lapsed, Board, basis recommendation of the Compensation Committee, has withdrawn and revoked the said old scheme effective 1-4-2021.

19. RISK MANAGEMENT

The Board of directors has developed and implemented risk management policy for the Company. Pursuant to the Listing Regulations, the Board has constituted Risk Management Committee and delegated monitoring and review of the risk management plan to the Committee. Committee would periodically review status of mitigation measures taken in respect of risk management plan and would report progress thereof and new risks identified to the Board and Audit Committee. Board at present does not perceive any element of risk, which may threaten existence of Profit before tax atRs. 593.71 crores registered growth of 74.85% mainly due to higher sales of chronic segment products, lower the Company.

20. INTERNAL FINANCIAL CONTROLS

The Board has adopted internal financial controls encompassing policies and procedures for ensuring the orderly and efficient conduct of the business, including adherence to Company’s policies, safeguarding the Company’s assets, prevention and detection of fraud and errors, accuracy and completeness of the accounting records and timely preparation of reliable financial information. The specific internal financial to financial statements include internal audit and processes relating to preparation of financial statements, adoption of well-defined standard operating procedure for business transactions and compliance relating thereto, use of ERP for accuracy and control, review of periodically prepared financial statements with objective to ensure that financial statements present true and fair view and are sufficient/credible and in compliance with legal and regulatory requirement. The Board has appointed Ernst & Young LLP as internal auditor to periodically audit systems and controls in all key areas of operations to ascertain effective functioning of internal controls including internal financial controls. In the opinion of the Board, the Company has adequate internal controls with reference to the financial statements. Neither management of the Company has come across any instance of fraud during the year 2020-21 nor the auditors of the Company has reported any such instance to the Audit Committee.

21. LOANS, GUARANTEES AND INVESTMENTS

During the year, the Company has not given any loan or guarantee or made any investment attracting the provisions of Section 186 of the Companies Act, 2013. Hence, there is no information to be furnished pursuant to Section 134(3)(g) of the Companies Act, 2013.

22. COST RECORDS

The Company is required to maintain cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013, and such accounts and records are duly made and maintained by the Company. The Company is further required to get such cost records audited by a cost auditor in accordance with the Companies (Cost Records and Audit) Rules, 2014 and furnish cost audit report received from the cost auditor to the or material order affecting the going concern Central Government within the prescribed time. The Company is in compliance with these provisions.

23. SECRETARIAL AUDIT REPORT

Ashish Bhatt & Associates, Practising Company Secretaries, Secretarial Auditor of the Company, carried out secretarial audit for the financial year 2020-21 as the Companies Act, 2013 and the rules made there under. The secretarial audit report given by the said auditor is annexed to this report as Schedule-J.

24. AUDITORS

DNV & Co., Chartered Accountants, (having firm registration no. 102079W), auditor of the Company, resigned during the year in order to enable the Company to appoint auditors who have more acceptability among institutional investors as also auditors, who have resources to assign across geographies in which the Company and its subsidiaries function so as to bring time and cost efficiencies. This resignation became effective after signing limited review report for quarter ended 30-9-2020 on 10-11-2020. Board, basis recommendation of the Audit Committee, appointed Deloitte Haskins & Sells LLP, (having firm registration no.117366W/W-100018) as auditor in casual vacancy, which appointment was also approved by members of the Company on 23-12-2020. Deloitte Haskins & Sells LLP thus hold office up to the date of ensuing annual general meeting. Board, on the basis of recommendation of the Audit Committee, now proposes to appoint Deloitte Haskins & Sells LLP as auditor to hold office as such for a term of five (5) years commencing from 23-12-2020 (being the date of passing of resolution through postal ballot for their appointment as auditors in casual vacancy) until conclusion of the 49th annual general meeting of the Company at such remuneration as may be agreed by the Board of directors with the auditors. Board recommends appointment of Deloitte Haskins & Sells LLP to the members for approval.

25. OTHER DISCLOSURES AND CONFIRMATIONS

Board has to make further disclosures and provide confirmations, as required, as under:

The Company has placed annual return referred to in sub-section (3) of section 92 on its website www.jbcpl.com.

No regulator or court or tribunal has passed, during the year, any and significant Company’s operations in future.

The Company has complied with applicable Secretarial Standards specified by the Institute of Company Secretaries of India and approved by the Central Government under Section 118(10) of the

Companies Act, 2013.

The Company has complied with the provisions relating to the providedunderSection204of constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

26. HEALTH AND SAFETY

The Company continues to accord high priority to health and safety of employees and workmen at all manufacturing locations. Annual medical check-up of all employees at all sites was carried out. The Company also conducted safety training programmes and mock-drills for increasing disaster preparedness awareness among all employees at the plants. There was no casualty at any site during the year.

For and on behalf of the Board of Directors

Ranjit Shahani

Chairman

Place : Mumbai

Date : June 14, 2021

   

J B Chemicals & Pharmaceuticals Ltd Company Background

Incorporation Year1976
Registered OfficeNeelam Centre 4th Floor,B-Wing Hind Cycle Road Worli
Mumbai,Maharashtra-400030
Telephone91-022-2482 2222/2493 0918,Managing Director
Fax91-022-24930534
Company Secretary
AuditorDNV & Co/Deloitte Haskins & Sells LLP
Face Value2
Market Lot1
ListingBSE,MSEI ,NSE,
RegistrarDatamatics Financial Services
Plot No B-5 MIDC ,Part B Cross Lane ,Marol Andheri(E) ,Mumbai-400093

J B Chemicals & Pharmaceuticals Ltd Company Management

Director NameDirector DesignationYear
Padmini Khare Kaicker Non-Exec. & Independent Dir. 2021
Sumit Bose Non-Exec. & Independent Dir. 2021
Ranjit Shahani. Non-Exec. & Independent Dir. 2021
Sanjay Nayar Non-Exec & Non-Independent Dir 2021
Prashant Kumar. Non-Exec & Non-Independent Dir 2021
Ananya Tripathi Non-Exec & Non-Independent Dir 2021
Nikhil Chopra Whole Time Director & CEO 2021
GAURAV TREHAN Non-Exec & Non-Independent Dir 2021

J B Chemicals & Pharmaceuticals Ltd Listing Information

Listing Information
BSE_500
BSE_HC
CNX500
BSESMALLCA
CNXSMALLCA
BSEALLCAP
SML250
MSL400
NFTYMSC400
NFTYSC50
NFTYSC250
NF500M5025

J B Chemicals & Pharmaceuticals Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Pharmaceuticals NA 0001588.3108
Export Incentives NA 00028.8393
Product Development Services NA 00011.9536
Exchange Rate Difference NA 0005.9318
Sale of Scrap NA 0002.1403
Other Operating Revenues NA 0001.7258
Government Grant NA 0000.9114
Manufacturing Charges NA 0000.798
Insurance Claims NA 0000.1334
Bulk Drugs Kg 0000
Active Pharmaceutical Ingredi NA 0000
Ampoules - Manufacturing GoodsNA 0000
Ampoules-Traded Goods NA 0000
Bulk-API-Manufacturing Goods NA 0000
Capsules No 0000
Capsules-Manufacturing Goods NA 0000
Capsules-Traded Goods NA 0000
Injections / Vials No 0000
Liquds-Manufacturing Goods NA 0000
Liquids Ltr0000
Liquids-Traded Goods NA 0000
Ointment Kg 0000
Ointments-Manufacturing Goods NA 0000
Ointments-Traded Goods NA 0000
Others - Traded NA 0000
Sales NA 0000
Other Raw & Packing Materials NA 0000
Others NA 0000
Cartridges No 0000
Powder-Manufacturing Goods NA 0000
Powders Kg 0000
Powder-Traded Goods NA 0000
Tablets No 0000
Tablets-Manufacturing Goods NA 0000
Tablets-Traded Goods NA 0000

Contact us Contact us